Orgenesis Inc
Change company Symbol lookup
Select an option...
ORGS Orgenesis Inc
LYFT Lyft Inc
AROC Archrock Inc
PACK Ranpak Holdings Corp
NVEE NV5 Global Inc
YARIY Yara International ASA
HYB New America High Income Fund
ACV Virtus Diversified Income & Convertible Fund
XLO Xilio Therapeutics Inc
ORN Orion Group Holdings Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Orgenesis Inc. is a global biotech company that is operating to unlock the potential of cell and gene therapies (CGTs). The Company is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). It has developed a Point of Care Platform (POCare Platform) comprised of three enabling components, which includes a pipeline of POCare advanced therapies that are designed to be processed and produced, automated closed POCare technology systems, and a worldwide network of POCare research institutes and hospitals (POCare Network). Its products in clinical use include KYSLECEL, Tissue Genesis Icellator for Cell Assisted Lipotransfer, Cartil-S Autologous products for the treatment of osteoarthritis, and Chondroseal Autologous products for the treatment of cartilage defects.

Closing Price
$2.52
Day's Change
0.13 (5.44%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.54
Day's Low
2.45
Volume
(Light)
Volume:
23,051

10-day average volume:
35,350
23,051

Tesla stock price target slashed by Wedbush's Ives on China's 'epic disaster,' Twitter 'circus show'

8:05 am ET May 19, 2022 (MarketWatch)
Print

Shares of Tesla Inc. (TSLA) dropped 1.6% toward a nine-month low in premarket trading Thursday, after Wedbush analyst Dan Ives slashed his price target by 29%, citing "hard to ignore" headwinds in China, as COVID-related lockdowns have reduced demand. Ives reiterated the outperform rating he's had on the electric vehicle maker since April 2021 but cut his price target to $1,000 from $1,400. "The success of the China story on both the supply and demand side are the linchpins to our long term bull thesis in Tesla," Ives wrote in a note to clients. "That said, the reality is the current Shanghai lockdowns have been an epic disaster so far in the June quarter and we expect Tesla to see modest delivery softness this quarter with a slower growth trajectory in the key China region into the [second half of the year]." He added that the "circus show" of Tesla Chief Executive Elon Musk's bid to buy Twitter Inc. (TWTR) has been a "black eye" for Tesla. "While the Twitter situation in theory does not impact the Tesla fundamental story, the distraction risks for Musk (perception is reality) are hard to ignore at a time that the Tesla ecosystem have never needed Musk more with the worst supply chain crisis seen in modern history," Ives wrote. The stock has plunged 32.8% year to date through Wednesday, while the S&P 500 has declined 17.7%.

-Tomi Kilgore

	

(END) Dow Jones Newswires

May 19, 2022 08:05 ET (12:05 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.